Eli Lilly Lawsuits: Mounjaro and Zepbound Injuries, Insulin Prices and Florida's September 2026 Case
Questions about this case?
AI Legal Assistant · free · answers in seconds · general information, not legal advice
There is no single Eli Lilly lawsuit. The maker of Mounjaro, Zepbound, Trulicity and Humalog is defending injury claims over its GLP-1 drugs and a large group of insulin-pricing cases — and on September 22, 2026, Florida's Attorney General announced a new insulin suit against it. As of September 30, 2026, none of these cases has a settlement, fund or claim form for patients.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Different Lawsuits Claim
GLP-1 injuries. Since August 2023, patients have sued Lilly and Novo Nordisk over injuries they allege followed use of incretin medicines — on Lilly's side Mounjaro, Zepbound (both tirzepatide) and Trulicity. One group of cases alleges gastrointestinal injuries; a second, separate group alleges sudden vision loss from damage to the optic nerve (NAION). Which injuries qualify and what proof the court demands: our GLP-1 lawsuit tracker.
Insulin prices. Since 2017, consumers, states, counties, Native American tribes, school districts, health plans and others have sued Lilly, other insulin makers and pharmacy benefit managers (PBMs) over insulin pricing and the rebates manufacturers pay PBMs. The claims include consumer protection, fraud, racketeering and antitrust. Florida's new suit alleges that the companies “inflated published list prices for insulin and related diabetes drugs” and paid rebates and fees to PBMs for preferred formulary placement.
Lilly as plaintiff. Lilly also sues: it challenges the government's 340B drug-discount rules, and its filings say it will keep considering “filing lawsuits where appropriate” against sellers of counterfeit and mass-compounded versions of its GLP-1 drugs.
These are allegations, not findings. Lilly says it intends to “vigorously prosecute or defend” its position.
Case Details
GLP-1 stomach and bowel injuries: In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, U.S. District Court for the Eastern District of Pennsylvania, Judge Karen S. Marston — 4,022 pending cases across both manufacturers on the Judicial Panel on Multidistrict Litigation's September 1, 2026 report (court orders).
GLP-1 vision loss (NAION): a separate MDL No. 3163, same court and judge — 216 pending cases on the same report. Lilly reports similar cases in Delaware, Indiana and New Jersey state courts, plus two class action petitions in Israel and two in Canada.
Insulin pricing: In re: Insulin Pricing Litigation, MDL No. 3080, U.S. District Court for the District of New Jersey, Judge Brian R. Martinotti, created by a JPML order of August 3, 2023 — 516 pending cases (618 over the life of the MDL) on September 1, 2026 (court page).
Florida: a state enforcement action in Florida's Eleventh Judicial Circuit with two counts under the Florida Deceptive and Unfair Trade Practices Act and one under the Florida Antitrust Act (Attorney General's release).
Status on September 30, 2026: Nothing to Claim
GLP-1 injury cases: the court scheduled a five-day Rule 702 (“Daubert”) hearing on expert evidence for September 14–18, 2026. As of September 30, 2026, the court's list of MDL 3094 orders shows no ruling from it — its newest entry is the August 28 scheduling order. Lilly's August 2026 quarterly report describes no settlement of these cases.
Insulin MDL: the court runs separate tracks for state attorney-general claims, putative (proposed) class actions and suits by self-funded health plans. On July 14, 2026 it set a briefing schedule for motions to compel arbitration, with replies due October 14, 2026. Lilly settled insulin-pricing allegations with New York in 2023 and Minnesota in 2024, but says those agreements “involved no monetary payments.”
Newest fronts: Florida's suit (September 22, 2026); a July 2026 Michigan Supreme Court decision reversing an appeals-court win for Lilly in the state attorney general's bid to investigate its insulin sales; and Novo Nordisk's July 21, 2026 false-advertising suit against Lilly over ads comparing GLP-1 drugs.
Follow this case
There's no claim deadline yet. We'll email you if a settlement opens a claim period.
Which Case Could Involve You
You took Mounjaro, Zepbound or Trulicity and were diagnosed with a serious stomach or bowel injury, or sudden vision loss. The GLP-1 MDLs are collections of individual injury lawsuits, not class actions: nobody is included automatically, and each person files their own case, usually through a lawyer. Injury tracks and what firms screen for: our Ozempic and GLP-1 lawsuit calculator; for vision loss, our NAION tracker.
You paid for Lilly insulin such as Humalog. Consumers are among the plaintiffs in the insulin MDL, and Lilly describes their cases as putative class actions. There is nothing to sign up for today.
You live in Florida and pay list price for insulin. Florida's case is brought by the state, not a class. The Attorney General says the uninsured, people in a deductible and people on percentage-based coinsurance are charged against the list price, not the negotiated one.
You are a health plan. Third-party payers are plaintiffs in the insulin MDL, and a certified class of payers is suing Takeda and Lilly over Actos. Neither is a patient case.
What Anyone Has Been Paid So Far
One Lilly case has gone against the company at trial, but it pays no patients. In a whistleblower (qui tam) case over how Lilly and Takeda calculated “average manufacturer prices,” a jury found for the whistleblower in August 2022, the Seventh Circuit affirmed in September 2025, and the Supreme Court declined review in May 2026.
If a consumer class case ever settles, a court-appointed administrator notifies class members directly. Until then, any “Lilly payout” offer is not real.
Eli Lilly Litigation Timeline
- 1
2017 — The First Insulin Pricing Suits
Consumers, states, counties and others begin suing Lilly, other insulin makers and PBMs over insulin prices and rebates, according to Lilly's filings.
- 2
August 2023 — Insulin MDL and First GLP-1 Suits
On August 3, 2023 the JPML sends federal insulin-pricing cases to New Jersey as MDL 3080 before Judge Brian R. Martinotti. The same month, the first GLP-1 injury suits naming Lilly are filed, per Lilly.
- 3
February 2024 — GLP-1 Injury MDL Opens
MDL 3094 gets under way in the Eastern District of Pennsylvania before Judge Karen S. Marston; its first case management order is dated February 15, 2024. Vision-loss claims later get their own MDL 3163.
- 4
July 2026 — Three New Fronts
Michigan's Supreme Court reverses an appeals-court win for Lilly in the attorney general's insulin investigation case; Novo Nordisk sues Lilly on July 21 over comparative-efficacy ads; generic makers notify Lilly of applications to copy Mounjaro and Zepbound.
- 5
September 14–18, 2026 — GLP-1 Expert Hearing
The Rule 702 evidentiary hearing on cross-cutting issues 2 and 3 was scheduled for these dates in MDL 3094. As of September 30, 2026, no ruling appears on the court's orders page.
- 6
September 22, 2026 — Florida Sues Lilly
Attorney General James Uthmeier announces a suit against Lilly, Novo Nordisk, Sanofi, CVS Caremark, Express Scripts, OptumRx and rebate aggregators Zinc, Ascent and Emisar over insulin and related diabetes-drug prices.
Three Things to Watch For
Lilly's weight-loss and diabetes drugs are heavily advertised, and so are the lawsuits about them:
“Claim your Mounjaro settlement” pages
There is no settlement in either GLP-1 MDL and no official administrator. A site that asks for your prescription history and Social Security number to “secure your payout” is collecting leads or data, not filing a claim.
“Lilly insulin refund” calls and texts
Lilly's insulin settlements with New York and Minnesota paid no money, and Florida's case is brought by the state. Anyone asking for a fee, card number or bank details to release an insulin refund is not acting for any court.
“Lilly” tirzepatide from unknown sellers
Lilly's own filings warn of “counterfeit or mass-compounded drugs sold under our brand name.” A seller that points to lawsuit headlines as proof its Mounjaro or Zepbound look-alike is legitimate is proving nothing — ask your pharmacist.
Eli Lilly Lawsuit — Questions People Ask
Is there an Eli Lilly lawsuit settlement I can claim?
No. As of September 30, 2026, there is no settlement, fund or claim form for patients in the GLP-1 injury MDLs, the insulin pricing MDL or Florida's new case, and Lilly's filings through its August 2026 quarterly report disclose none that pays consumers. For cases that are paying now, see open class action settlements.
Is there an Eli Lilly class action I can join?
Not by signing up. The Mounjaro, Zepbound and Trulicity injury cases are individual lawsuits grouped in MDLs, not a class action — each patient files their own. The consumer insulin cases are putative (proposed) class actions; if a class is certified or settles, members are notified and included unless they opt out. Florida's case is a state enforcement action with nothing to join.
Is Mounjaro part of the Ozempic lawsuit?
Yes. Lilly says patients have sued it and Novo Nordisk since August 2023 over incretin medicines including Mounjaro, Trulicity and Zepbound, and that most U.S. cases sit in two federal MDLs in Pennsylvania: MDL 3094 (gastrointestinal, 4,022 pending on September 1, 2026) and MDL 3163 (vision loss, 216 pending). Those totals cover both manufacturers. Full status: GLP-1 lawsuit tracker.
Can I get money back for what I paid for Lilly insulin?
Not today. Consumers are among the plaintiffs in the insulin pricing MDL (No. 3080, District of New Jersey), which has its own track for putative class actions, but Lilly's filings report no settlement with consumers. Its New York and Minnesota settlements involved no monetary payments. The court set January 14, 2021 as a constructive-notice date for statute-of-limitations purposes — ask a lawyer how that affects you.
What is Florida's insulin lawsuit against Eli Lilly?
Announced September 22, 2026, it accuses Lilly, Novo Nordisk and Sanofi — which the Attorney General says supply more than 90 percent of the world's insulin — plus three PBMs that process roughly 80 percent of U.S. prescriptions and three rebate aggregators of inflating list prices in exchange for formulary placement. It cites testimony by a Lilly executive that of every $280 vial of Humalog, Lilly hands about $210 back to PBMs as rebates and discounts. It also covers GLP-1 and combination products including Trulicity. These are allegations; the PBM side is on our OptumRx lawsuit page.
Is Lilly suing compounding pharmacies and telehealth sellers?
Lilly says it keeps seeing “counterfeit, misbranded, adulterated, and mass-compounded incretins” and “will continue to consider all options, including filing lawsuits where appropriate.” It also says the FDA confirmed in late 2024 that the tirzepatide shortage had ended and that compounding pharmacies must stop mass production. These are cases Lilly brings as plaintiff; nothing in its filings describes payments to patients. Novo Nordisk's side of the compounding fight: our Novo Nordisk lawsuit page.
Is there an Eli Lilly shareholder lawsuit?
Lilly's August 2026 quarterly report describes no securities class action among its significant legal matters. The class cases it does describe are brought over insulin prices, by Mosaic Health over the 340B drug-discount program (a putative antitrust class action the Second Circuit revived; Lilly asked the Supreme Court to review it in March 2026) and by third-party payers over Actos.
Are generic companies trying to copy Mounjaro and Zepbound?
Yes. In July 2026 Lilly received notice that multiple generic companies had filed applications to market generic versions of Mounjaro and/or Zepbound before some or all of the listed patents expire; Lilly said it intends to sue for patent infringement. Separately, Novo Nordisk sued Lilly on July 21, 2026 in federal court in New Jersey, alleging false advertising in direct-to-consumer ads about the comparative efficacy of GLP-1 drugs.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.